ASP-2802

N/A

Report date: 2025/01/07 20:00:06

Base Information

Drug NameASP-2802

Drug Alias NameMicAbodyTM ProteinMACTASP2802ASP-2802

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAstellas Pharma Global Development Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAstellas Pharma Global Development Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A